Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

20081,173 citationsJournal Articlebronze Open Access

Authors

Patrick Marcellin · Université Paris Cité

E. Jenny Heathcote · University of Toronto

Marı́a Buti · Vall d'Hebron Hospital Universitari

Ed Gane · Middlemore Hospital

Robert A. de Man

Zahary Krastev · University Hospital St. Ivan Rilski

G. Germanidis · Papageorgiou General Hospital

Abstract

Among patients with chronic HBV infection, tenofovir DF at a daily dose of 300 mg had superior antiviral efficacy with a similar safety profile as compared with adefovir dipivoxil at a daily dose of 10 mg through week 48. (ClinicalTrials.gov numbers, NCT00116805 and NCT00117676.)

Topics & Keywords

Hepatitis B Virus Studies Hepatitis C virus research Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 359, Issue 23, pp. 2442-2455

DOI: 10.1056/nejmoa0802878

Field-Weighted Citation Impact: 61.96